NCT06540963 2026-03-02
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Milton S. Hershey Medical Center
Phase 2 Recruiting
Clinical Trials
12 trialsNCT03496766 2025-03-05
Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS
Spanish Lung Cancer Group
Phase 2 Terminated
NCT02535650 2022-03-08
Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma
Samsung Medical Center
Phase 2 Unknown
NCT00847223 2018-08-23
Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma
Lymphoma Study Association
Phase 2 Terminated
NCT00047216 2015-07-23
Tipifarnib in Treating Patients With Recurrent Bladder Cancer
University Health Network, Toronto
Phase 2 Completed
NCT00005848 2013-07-11
R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Fox Chase Cancer Center
Phase 2 Completed
NCT00005041 2012-11-09
R115777 in Treating Patients With Relapsed Small Cell Lung Cancer
NYU Langone Health
Phase 2 Completed
NCT00012350 2012-10-23
Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00054470 2012-06-29
Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Withdrawn
NCT00005989 2011-08-04
R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
Mayo Clinic
Phase 2 Completed
NCT00510939 2009-08-14
HEMOS AML 0106
University of Bologna
Phase 2 Unknown
NCT00210028 2006-11-14
Study Assessing Efficacy of ZARNESTRAâ„¢ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer
Institut Claudius Regaud
Phase 2 Terminated